Bio-Rad introduces new antibodies for in vitro research, commercial applications
Bio-Rad Laboratories, a specialist in life science research and clinical diagnostic products, has extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies that are specific for ipilimumab (Yervoy) and the ipilimumab/CTLA-4 drug-target complex. These highly specific and high-affinity antibodies are suitable for bioanalytical and patient drug level monitoring assays for the immune checkpoint inhibitor: ipilimumab.
Bio-Rad also announced the launch of a range of anti-certolizumab pegol inhibitory antibodies to support the development of assays for therapeutic drug monitoring of tumor necrosis factor (TNF) alpha inhibitors.
Ipilimumab activates the immune system by inhibiting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that hinders the destruction of cancerous cells, to treat cancers such as melanoma. The four anti-ipilimumab antibodies inhibit the binding of the drug to its target, CTLA-4, and therefore detect free drug. These antibodies are suitable for developing pharmacokinetic (PK) bridging ELISAs and being used as a surrogate positive control (or reference standard) for anti-drug antibody assays. The drug-target complex binder specifically recognizes the ipilimumab/CTLA-4 complex and can be used as the detection antibody in a PK antigen capture assay as an alternative format to the bridging ELISA.
The recombinant monoclonal anti-idiotypic antibodies are generated using the Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures a consistent and secure supply.
The anti-ipilimumab antibodies are approved for in vitro research and for commercial applications of in vitro testing services that support preclinical and clinical drug and biosimilar development and patient monitoring.
Anti-certolizumab pegol inhibitory antibodies
The range of recombinant monoclonal anti-idiotypic antibodies comprises three antibodies that are highly specific for the monoclonal antibody Fab fragment certolizumab pegol (Cimzia) and inhibit the binding of this drug to its target: TNF alpha. The antibodies are fully human in full length IgG format and can be used as a surrogate positive control or calibration standard for an ADA assay to measure levels of patient anti-drug antibodies.
TNF alpha inhibitors are used to treat a wide range of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis. The levels of serum drug and ADA concentrations are monitored in patients receiving TNF alpha antagonists to help guide clinical decision making, optimize treatment, improve outcomes, and reduce healthcare costs.
The anti-certolizumab pegol antibodies are approved for in vitro research and for commercial applications of in vitro testing services that support preclinical and clinical drug and biosimilar development and patient monitoring.